David H. Kirn
Net Worth
Last updated:
What is David H. Kirn net worth?
The estimated net worth of Dr. David H. Kirn is at least $16,700,581 as of 10 Jul 2024. He owns shares worth $6,905,678 as insider, has earned $7,690,313 from insider trading and has received compensation worth at least $2,104,590 in 4D Molecular Therapeutics, Inc..
What is the salary of David H. Kirn?
Dr. David H. Kirn salary is $701,530 per year as Co-Founder, Chief Executive Officer, Pres & Director in 4D Molecular Therapeutics, Inc..
How old is David H. Kirn?
Dr. David H. Kirn is 62 years old, born in 1963.
What stocks does David H. Kirn currently own?
As insider, Dr. David H. Kirn owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | Co-Founder, Chief Executive Officer, Pres & Director | 1,059,153 | $6.52 | $6,905,678 |
What does 4D Molecular Therapeutics, Inc. do?
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
David H. Kirn insider trading
4D Molecular Therapeutics, Inc.
Dr. David H. Kirn has made 16 insider trades between 2022-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 92,001 units of FDMT stock on 8 Feb 2024. As of 10 Jul 2024 he still owns at least 1,059,153 units of FDMT stock.
4D Molecular Therapeutics key executives
4D Molecular Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. David E. Schaffer Ph.D. (55) Co-Founder, Chief Scientific Advisor & Independent Director
- Dr. David H. Kirn (62) Co-Founder, Chief Executive Officer, Pres & Director
- Dr. John F. Milligan (64) Executive Chairman
- Dr. Robert S. Fishman (63) Chief Medical Officer & Therapeutic Area Head of Pulmonology
- Mr. August J. Moretti Esq., J.D. (74) Chief Financial Officer